Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

British Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2010, Pages 617-625

  Ruf, Peter ^a   Kluge, Michael ^b   Jäger, Michael ^a   Burges, Alexander ^c   Volovat, Constantin ^d   Heiss, Markus Maria ^e   Hess, Jürgen ^g   Wimberger, Pauline ^f   Brandt, Birgit ^b   Lindhofer, Horst ^a,g  

^a TRION Research GmbH   (Germany)

^b Fresenius Biotech   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Centrul de Oncologie Medicala   (Romania)

^e Klinik für Unfallchirurgie Orthopädie und Sporttraumatologie   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g TRION Pharma GmbH   (Germany)

Author keywords

Catumaxomab; Immunogenicity; Intraperitoneal infusion; Malignant ascites; Pharmacokinetics

Indexed keywords

CATUMAXOMAB; DRUG ANTIBODY; PARACETAMOL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EFFECTOR CELL; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; MOUSE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ASCITES; BIOLOGICAL AVAILABILITY; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; NEOPLASMS;

EID: 77952078636     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03635.x     Document Type: Article

References (25)

1. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999 163 : 1246 1252. (Pubitemid 29352740)
2. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000 83 : 261 266. (Pubitemid 30411727)
3. Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 2008 10 : 273 284. (Pubitemid 351799279)
4. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001 98 : 2526 2534. (Pubitemid 33763128)
5. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007 97 : 315 321. (Pubitemid 47196752)
6. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005 117 : 435 443. (Pubitemid 41429567)
7. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996 83 : 6 14.
8. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007 18 : 945 949. (Pubitemid 47054094)
9. az-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993 9 : 516 521.
10. De AM, Buley ID, Heryet A, Gray W. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992 3 : 111 117.
11. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Perol M, Genin C. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res 2005 11 : 6862 6867. (Pubitemid 41428741)
12. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jager M, Strohlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007 13 : 3899 3905. (Pubitemid 47037597)
13. Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A. Treatment of malignant pleural effusions with the trifunctional antibody catumaxomab (removab) (anti-EpCAM × anti-CD3): results of a phase 1/2 study. J Immunother 2009 32 : 195 202.
14. Parsons S, Murawa PX, Koralewski P, Kutarska E, Kolesnik OO, Stroehlein MA, Lahr A, Jaeger M, Heiss M. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: a phase II/III study. J Clin Oncol 2008 26 (Suppl.): abstr 3000.
15. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006 42 : 589 597. (Pubitemid 43343680)
16. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004 35 : 122 128. (Pubitemid 38133932)
17. Stroehlein MA, Gruetzner KU, Tarabichi A, Jauch KW, Bartelheim K, Lindhofer H, Von Roemeling R, Heiss MM. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis. J Clin Oncol 2006 24 : 2544. 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement).
18. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004 93 : 2645 2668.
19. Frodin JE, Lefvert AK, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res 1990 50 : 4866 4871. (Pubitemid 20257901)
20. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005 5 (Suppl. 1 S37 47. (Pubitemid 41243344)
21. Mobus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003 189 : 28 36. (Pubitemid 36886520)
22. Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 2007 56 : 1637 1644. (Pubitemid 47094393)
23. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999 17 : 1851 1857. (Pubitemid 29269257)
24. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004 104 : 948 955. (Pubitemid 39043667)
25. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, Le PA, Bardos P, Paintaud G, Cartron G. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2008 113 : 3765 3772.